SCHEMBL26433445

SCHEMBL26433445

CCCn1c(C)cc2cc(C(C)(C)C)ccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.51
ALDH1A1 P00352 4/20 0.51
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
GAA P10253 1/20 0.51
PGR P06401 2/20 0.42
RORA P35398 2/20 0.42
RORC P51449 2/20 0.42
RORB Q92753 2/20 0.42
KCNH2 Q12809 1/20 0.40
TP53 P04637 4/20 0.39
TSHR P16473 1/20 0.37
HTR1D P28221 1/20 0.36
MAPT P10636 4/20 0.36
HTT P42858 2/20 0.36
NPC1 O15118 1/20 0.36
CYP1A2 P05177 1/20 0.36
HSP90AA1 P07900 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13921919 0.78 RORA (0.57) KDM4EALDH1A1PGRRORARORC
SCHEMBL13640280 0.77 ALDH1A1 (0.54) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL6325712 0.74 TP53 (0.59) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL31021975 0.74 TP53 (0.59) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL11607006 0.73 MEN1 (0.50) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL12745350 0.70 NR1I2 (0.38) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL3483496 0.69 MEN1 (0.45) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL2627061 0.68 PRKCI (0.55) ALDH1A1KCNH2HTR1DPKMHPGD
SCHEMBL13637248 0.68 KCNH2 (0.50) KDM4EMEN1KMT2ARORCKCNH2
SCHEMBL20853226 0.68 ALDH1A1 (0.68) KDM4EALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11639347-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11639347-B2 Modulators of ATP-binding cassette transporters CFTR, ABCB1, ABCC2 KDM4E 4235/4885ALDH1A1 1961/4885MEN1 4687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.